阅读说明：本技术 一种用于辅助治疗二型糖尿病的组合物 (Composition for adjuvant treatment of type II diabetes ) 是由 丰明乾 朱元奎 刘路 于 2021-09-08 设计创作，主要内容包括：本发明涉及一种用于辅助治疗二型糖尿病的组合物,包括以下重量份比原料N-甲基吗啉1-9份、虾青素0.1～2。本发明的优点：清除体内自由基、保护胰岛细胞、增加胰岛素的敏感性和抑制并发症。(The invention relates to a composition for adjuvant therapy of type II diabetes, which comprises the following raw materials, by weight, 1-9 parts of N-methylmorpholine and 0.1-2 parts of astaxanthin. The invention has the advantages that: scavenging free radicals in vivo, protecting islet cells, increasing insulin sensitivity, and inhibiting complications.)

1. A composition for use in the adjunctive treatment of type ii diabetes mellitus, comprising: comprises the following raw materials of 1-9 parts by weight of N-methylmorpholine and 0.1-2 parts by weight of astaxanthin.

2. The composition for the adjuvant treatment of type ii diabetes according to claim 1, wherein: the composition is one of tablet, powder, granule or capsule.

3. The composition for the adjuvant treatment of type ii diabetes according to claim 1, wherein: the composition is one of an orally administered formulation, a food product, a beverage, or a nutraceutical.

Technical Field

The invention relates to the technical field of diabetes treatment, in particular to a composition for adjuvant therapy of type II diabetes.

Background

Currently, more and more diseases are attacking human health. Since the middle of the twentieth century, chronic diseases affecting human health, such as hypertension, diabetes, coronary heart disease, malignant tumor, etc., are mainly involved. In recent years, with the improvement of the dietary level of people, the incidence rate of chronic diseases is also increasing year by year, especially diabetes mellitus, which is more and more popular among people, from the top to the elderly, and from the bottom to children, is likely to become diabetic. The prevalence rate of diabetes mellitus in adults in China is 11.6%, and the prevalence rate of diabetes mellitus in men and women is 12.1% and 11.0% respectively, which are very common diseases difficult to cure radically.

Type II diabetes develops later in life, and it is often the organs and tissues that lose their ability to respond effectively to insulin. Type II diabetes has previously been referred to as non-insulin dependent diabetes mellitus or adult-onset diabetes. Type II diabetes accounts for approximately 90% to 95% of all diagnosed cases of diabetes as assessed by CDC. Risk factors for type II diabetes include higher age, obesity, family history of diabetes, history of gestational diabetes, impaired glucose tolerance, lack of exercise, and race/ethnicity, affecting a person's physical health.

Disclosure of Invention

The technical problem to be solved by the invention is to solve the problems and provide a composition for adjuvant therapy of type II diabetes.

In order to solve the technical problems, the technical scheme provided by the invention is as follows: a composition for adjuvant treatment of type II diabetes comprises, by weight, 1-9 parts of N-methylmorpholine and 0.1-2 parts of astaxanthin.

Further, the composition is one of a tablet, a powder, a granule or a capsule.

Further, the composition is one of an orally administered formulation, a food product, a beverage, or a nutraceutical.

After adopting the structure, the invention has the following advantages: the invention is based on the combination of the aspects of eliminating free radicals in vivo, protecting islet cells, increasing the sensitivity of insulin and inhibiting complications, and provides a health nutrient or medicament for preventing and controlling diabetes and high-risk people.

Drawings

FIG. 1 is a control panel of a composition of the present invention for use in the adjunctive treatment of type II diabetes.

FIG. 2 is a diagram of a panel of compositions of the present invention for use in the adjunctive treatment of type II diabetes.

FIG. 3 is a graph of a composition of the present invention for use in adjuvant treatment of type II diabetes mellitus after 8 weeks.

Detailed Description

The present invention will be described in further detail with reference to the accompanying drawings.

With the combination of all the figures, the composition for adjuvant therapy of type II diabetes comprises the following raw materials, by weight, 1-9 parts of N-methylmorpholine and 0.1-2 parts of astaxanthin.

Further, the composition is one of a tablet, a powder, a granule or a capsule.

Further, the composition is one of an orally administered formulation, a food product, a beverage, or a nutraceutical.

In the specific implementation of the invention, 90 parts by weight of N-methylmorpholine and 10 parts by weight of astaxanthin are taken, and water is taken as an adhesive of a solvent to prepare wet granules; sieving the wet granules by a sieve of 10-40 meshes; drying the sieved granules at 20-80 ℃; and pressing and forming the dried granules by a tablet machine. The weight of each tablet was 300 mg.

20 female 8-week-old KM mice are selected, fed with high-fat and high-sugar feed for 30 days, and are subjected to intraperitoneal injection for 30mg/kg of body weight to measure STK for 2-4 days, and after confirming that the KM mice are obese, the KM mice are randomly divided into 2 groups.

Animals of each group were kept in an SPF (specific pathogen free) environment (room temperature 26 ℃ C., 12 hours day and night cycle) with free access to water. The experimental groups were gavaged daily for 12 weeks with the extract composition of the present invention.

Weighing animal body weight, fasting blood glucose (after fasting for 6h, cutting tail to draw blood, and measuring by rapid glucometer) glucose tolerance test (OGTT) (after fasting for 6h, feeding 2g/kg glucose for intragastric administration); data analysis was performed using T-test, p <0.05, as significant.

After 12 weeks of treatment, insulin tolerance experiments were performed. Fasting for 6h, and measuring tail vein blood sugar after injecting insulin (1U/kg) for 0min, 15min, 30min and 60 min.

When the composition of the invention is used for treating diabetic mice, as shown in figure 1, compared with a control group, the fasting blood glucose of an experimental group is obviously reduced. As shown in fig. 2, the insulin tolerance of the experimental group was significantly improved. Meanwhile, as shown in fig. 3, the body weight of mice in the experimental group was statistically different from that in the control group after 8 weeks of treatment with the composition of N-methylmorpholine (NMN) + astaxanthin (ASTA). The above results suggest that the composition of N-methylmorpholine (NMN) + astaxanthin (ASTA) has a certain therapeutic effect on diabetic mice.

The working principle of the invention is as follows: ingestion of high calorie foods destroys the anabolism of NAD +, and supplementation with N-methylmorpholine increases insulin sensitivity and ameliorates age-induced glucose intolerance. Astaxanthin has strong antioxidation effect, and can directly eliminate oxygen free radicals in cells. Protect the corresponding tissues from being damaged, recover the normal regulation function of the pancreatic islets, and can also inhibit the diabetic complications by removing the 'sugar virus' from the source.

The present invention and its embodiments have been described above, but the description is not limitative, and the actual structure is not limited thereto. In summary, those skilled in the art should appreciate that they can readily use the disclosed conception and specific embodiments as a basis for designing or modifying other structures for carrying out the same purposes of the present invention without departing from the spirit and scope of the invention as defined by the appended claims.